Equities researchers at Oppenheimer assumed coverage on shares of Benitec Biopharma (NASDAQ:BNTC – Get Free Report) in a research report issued to clients and investors on Wednesday, Briefing.com reports. The firm set an “outperform” rating and a $35.00 price target on the biotechnology company’s stock. Oppenheimer’s price target would indicate a potential upside of 256.78% from the company’s previous close.
A number of other brokerages have also recently commented on BNTC. JMP Securities raised their price objective on shares of Benitec Biopharma from $16.00 to $18.00 and gave the stock a “market outperform” rating in a research note on Monday. Leerink Partnrs upgraded shares of Benitec Biopharma to a “strong-buy” rating in a research report on Monday, July 22nd. Guggenheim initiated coverage on shares of Benitec Biopharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $17.00 price objective for the company. Finally, Leerink Partners initiated coverage on shares of Benitec Biopharma in a research note on Monday, July 22nd. They set an “outperform” rating and a $13.00 target price on the stock. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $22.60.
Get Our Latest Research Report on Benitec Biopharma
Benitec Biopharma Stock Down 3.4 %
Hedge Funds Weigh In On Benitec Biopharma
A number of hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC increased its position in Benitec Biopharma by 20.3% during the third quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 1,102 shares during the last quarter. Nantahala Capital Management LLC acquired a new stake in shares of Benitec Biopharma during the 2nd quarter worth approximately $5,881,000. Simplify Asset Management Inc. purchased a new stake in shares of Benitec Biopharma during the 2nd quarter valued at approximately $358,000. Finally, Janus Henderson Group PLC lifted its holdings in Benitec Biopharma by 35.5% in the first quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock valued at $1,266,000 after acquiring an additional 64,092 shares during the last quarter. Institutional investors and hedge funds own 52.19% of the company’s stock.
About Benitec Biopharma
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Read More
- Five stocks we like better than Benitec Biopharma
- Energy and Oil Stocks Explained
- Johnson & Johnson Stock: Setting the Stage for 2025 Highs
- What is Put Option Volume?
- Bank of America Earnings Uncover Shifts in Consumer Spending
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- NVIDIA Stock Continues to Be Wall Street’s Favorite: Here’s Why
Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.